Verekitug Phase 2 Data Show 80% Responder Rate in Nasal Polyp Trial
The EAACI 2026 responder analysis adds to mounting evidence for targeted biologics in upper-airway inflammatory conditi…
The EAACI 2026 responder analysis adds to mounting evidence for targeted biologics in upper-airway inflammatory conditi…
Six-month interim results reinforce MC4R pathway as a viable therapeutic target, with Phase 3 development now in the ra…
As GLP-1 adoption accelerates, new CE data highlights the pharmacist's expanding role in bridging gaps between clinical…
The Utah-based brand has expanded from a single deer antler spray SKU to a full portfolio spanning pre-workouts, creati…
Phase 3 APEX data presented at EHA 2026 positions the KIT-targeting agent as a potential standard-of-care option in a r…
HUTCHMED's spleen tyrosine kinase inhibitor advances clinical evidence base as targeted hematology therapies draw renew…
As PEMF devices edge into recovery and biohacking categories, operator-grade reliability becomes a key differentiator f…
Single-dose durability data from EHA 2026 positions off-the-shelf CAR-T as a potential paradigm shift in hematologic on…
The partnership signals growing institutional appetite for lifestyle-medicine frameworks that embed nutrition and funct…
As contrast therapy retreats expand across Europe, finished-formulation brands are eyeing co-marketing and on-site nutr…
The shift reflects consumer fatigue with complex regimens and growing clinical evidence linking complete EAA profiles t…
As patient registries expand in pain research, nutraceutical developers gain potential real-world data infrastructure f…